IMMUNOTHERAPY

TIL infusions effective in HPV-associated cancers

Adoptive immunotherapy with infusion of ex vivo expanded tumour-infiltrating lymphocytes (TILs) is an attractive approach to anticancer therapy owing to the high levels of antitumour specificity that can be achieved. Now, the outcomes of a phase II study in which patients with human papillomavirus (HPV)-associated cervical (n = 18) and noncervical (n = 11) cancers reveal that this approach is feasible and is effective in some patients. TIL cultures were expanded ex vivo in the presence of tumour specimens and administered to patients as a single infusion following a nonmyeloablative chemotherapy conditioning regimen. Objective responses were observed in 28% of patients (5/18) with cervical cancer and in 18% (2/11) without. Two responses were complete and were ongoing at the time of analysis (at 67 and 53 months after infusion). The adverse event profile was consistent with that of the chemotherapy regimen: no infusion-related or autoimmune toxicities were reported.

References

Original article

  1. Stevanovic, S. et al. A phase II study of tumor-infiltrating lymphocyte therapy for human papillomavirus-associated epithelial cancers. Clin. Cancer Res. https://doi.org/10.1158/1078-0432.CCR-18-2722 (2018)

    Article  PubMed  Google Scholar 

Download references

Author information

Affiliations

Authors

Corresponding author

Correspondence to Peter Sidaway.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Sidaway, P. TIL infusions effective in HPV-associated cancers. Nat Rev Clin Oncol 16, 144 (2019). https://doi.org/10.1038/s41571-018-0160-6

Download citation

Search

Sign up for the Nature Briefing newsletter for a daily update on COVID-19 science.
Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing